US 12,435,146 B2
Anti-Flt-1 antibodies for treating Duchenne muscular dystrophy
Dennis Keefe, Lexington, MA (US); Hans De Haard, Zwijnaarde (BE); Natalie De Jonge, Zwijnaarde (BE); and Sofie Gabriels, Zwijnaarde (BE)
Assigned to Shire Human Genetic Therapies, Inc., Lexington, MA (US)
Filed by Shire Human Genetic Therapies, Inc., Lexington, MA (US)
Filed on Mar. 23, 2023, as Appl. No. 18/189,065.
Application 18/189,065 is a continuation of application No. 16/991,762, filed on Aug. 12, 2020, abandoned.
Application 16/991,762 is a continuation of application No. 15/564,976, granted, now 10,787,515, issued on Sep. 29, 2020, previously published as PCT/US2016/026352, filed on Apr. 7, 2016.
Claims priority of provisional application 62/307,645, filed on Mar. 14, 2016.
Claims priority of provisional application 62/144,251, filed on Apr. 7, 2015.
Prior Publication US 2024/0076387 A1, Mar. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 39/39566 (2013.01); A61K 2039/505 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/50 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/70 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 9 Claims
 
1. A polynucleotide encoding an anti-Flt-1 antibody or antigen-binding fragment thereof comprising (a) a variable light (VL) chain CDR1 defined by an amino acid sequence having identity to SEQ ID NO: 21, a VL CDR2 defined by an amino acid sequence having identity to SEQ ID NO: 24, a VL CDR3 defined by an amino acid sequence having identity to SEQ ID NO: 26, a variable heavy (VH) chain CDR1 defined by an amino acid sequence having identity to SEQ ID NO: 2, a VH CDR2 defined by an amino acid sequence having identity to SEQ ID NO: 6, and a VH CDR3 defined by an amino acid sequence having identity to SEQ ID NO: 16;
(b) a VL CDR1 defined by the amino acid sequence having identity to SEQ ID NO: 21, a VL CDR2 defined by the amino acid sequence having identity to SEQ ID NO: 24, a VL CDR3 defined by an amino acid sequence having identity to SEQ ID NO: 27, a VH CDR1 defined by the amino acid sequence having identity to SEQ ID NO: 2, a VH CDR2 defined by an amino acid sequence having identity to SEQ ID NO: 7, and a VH CDR3 defined by an amino acid sequence having identity to SEQ ID NO: 17;
(c) a VL CDR1 defined by the amino acid sequence having identity to SEQ ID NO: 21, a VL CDR2 defined by the amino acid sequence having identity to SEQ ID NO: 24, a VL CDR3 defined by the amino acid sequence having identity to SEQ ID NO: 26, a VH CDR1 defined by an amino acid sequence having identity to SEQ ID NO: 3, a VH CDR2 defined by an amino acid sequence having identity to SEQ ID NO: 12, and a VH CDR3 defined by the amino acid sequence having identity to SEQ ID NO: 17;
(d) a VL CDR1 defined by the amino acid sequence having identity to SEQ ID NO: 21, a VL CDR2 defined by the amino acid sequence having identity to SEQ ID NO: 24, a VL CDR3 defined by an amino acid sequence having identity to SEQ ID NO: 28, a VH CDR1 defined by the amino acid sequence having identity to SEQ ID NO: 2, a VH CDR2 defined by an amino acid sequence having identity to SEQ ID NO: 8, and a VH CDR3 defined by the amino acid sequence having identity to SEQ ID NO: 17; or
(e) a VL CDR1 defined by the amino acid sequence having identity to SEQ ID NO: 21, a VL CDR2 defined by the amino acid sequence having identity to SEQ ID NO: 24, a VL CDR3 defined by an amino acid sequence having identity to SEQ ID NO: 32, a VH CDR1 defined by the amino acid sequence having identity to SEQ ID NO: 3, a VH CDR2 defined by the amino acid sequence having identity to SEQ ID NO: 12, and a VH CDR3 defined by the amino acid sequence having identity to SEQ ID NO: 17.